用于预防产后出血的特兰胺酸:系统审查和个人患者数据元分析的协议
, Katharine Ker1, Haleema Shakur-Still1
1CTU Global Health Trials Group, London School of Hygiene & Tropical Medicine, London, WC1E 7HT, UK.
Gates open research
|August 21, 2023
概括
特兰胺酸 (TXA) 可能会预防产后出血,改善数百万人的结局. 这一系统性审查和元分析将评估TXA在所有分娩妇女的有效性和安全性.
科学领域:
- 产科和妇科 产科和妇科
- 药理学 药理学是指药理学的学科.
- 基于证据的医学 基于证据的医学
背景情况:
- 严重的产后出血是导致母亲死亡的主要原因.
- 推用于重症产后出血,但正在研究其预防性使用.
- 使用TXA预防产后出血可以显著改善全球的孕产妇结果.
研究的目的:
- 系统地审查和进行个人患者数据 (IPD) 对TXA预防产后出血的有效性和安全性的元分析.
- 根据患者的风险因素,出生类型,血红蛋白水平和给药时间来探索TXA效应的变化.
- 为临床决策提供强有力的证据,关于在分娩期间在所有妇女中使用TXA.
主要方法:
- 系统地搜索具有前性注册的随机对照试验 (RCT),涉及≥500名患者.
- 数据提取和偏差风险评估由两位独立作者.
- 使用一阶段模型分析主要结果的IPD元分析:危及生命的出血和血栓塞栓事件.
主要成果:
- 该部分将在研究完成后填写.
- 在IPD的元分析将提供TXA的好处和危害的精确估计.
- 亚组分析将确定影响TXA有效性和安全性的患者特征.
结论:
- 本次IPD元分析将解决关于TXA在预防产后出血中的作用的关键问题.
- 结果将为临床指南提供信息,并优化TXA的使用,以提高孕产妇的安全性.
- 这项研究旨在澄清TXA在分娩期间对所有妇女的益处风险平衡.
更多相关视频
03:07Author Spotlight: Developing a Safer and More Efficient Treatment Protocol for Wasting Marmoset Syndrome (WMS)
Published on: July 12, 2024
1000
09:04Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
Published on: September 10, 2018
9.8K
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
751
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
751
01:29Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
01:30Venous Thrombosis IV: Nursing Management
14
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
14
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K